Free tool
FAERS Monitor: Emgality
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761063 or its brand name (Emgality, Galcanezumab-Gnlm). Reports on generic versions are filed under their own applications.
Reports
32,317
Serious
4,007
12% of reports
Hospitalization
1,162
Death reported
89
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- injection site pain7,789
- migraine3,158
- underdose2,919
- headache2,509
- drug ineffective1,980
- product dose omission issue1,766
- injection site haemorrhage1,666
- incorrect dose administered1,197
- injection site erythema1,145
- accidental underdose1,068
- nausea852
- injection site swelling827
- injection site pruritus824
- fatigue795
- injection site reaction731
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 4 |
| 2016 | 4 |
| 2017 | 6 |
| 2018 | 140 |
| 2019 | 4,657 |
| 2020 | 6,640 |
| 2021 | 4,645 |
| 2022 | 3,737 |
| 2023 | 2,977 |
| 2024 | 3,150 |
| 2025 | 3,672 |
| 2026 | 2,685 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,021,842 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| accidental underdoseSignal | 1,068 | 52.1 | 49.0 | 49,524 |
| underdoseSignal | 2,919 | 27.1 | 26.1 | 70,570 |
| migraineSignal | 3,158 | 22.2 | 21.5 | 62,180 |
| injection site painSignal | 7,789 | 16.9 | 16.6 | 115,461 |
| injection site haemorrhageSignal | 1,666 | 13.8 | 13.2 | 19,499 |
| injection site pruritusSignal | 824 | 8.1 | 7.6 | 5,069 |
| injection site swellingSignal | 827 | 7.1 | 6.6 | 4,289 |
| injection site reactionSignal | 731 | 7.0 | 6.5 | 3,710 |
| injection site erythemaSignal | 1,145 | 6.1 | 5.7 | 4,810 |
| product dose omission issueSignal | 1,766 | 3.9 | 3.8 | 3,880 |
| incorrect dose administeredSignal | 1,197 | 3.4 | 3.2 | 2,065 |
| headacheSignal | 2,509 | 2.6 | 2.5 | 2,559 |
| drug ineffective | 1,980 | 1.0 | 0.9 | 1 |
| nausea | 852 | 0.7 | 0.7 | 113 |
| fatigue | 795 | 0.7 | 0.6 | 140 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.